Home JAK/STAT JAK inhibitor XL019 For research use only.

XL019

XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.

XL019 Chemical Structure

XL019 Chemical Structure

CAS: 945755-56-6

Selleck's XL019 has been cited by 7 publications

Purity & Quality Control

Batch: S703601 DMSO] 16 mg/mL] false] Water] Insoluble] false] Ethanol] Insoluble] false Purity: 99.01%
99.01

Other JAK Products

Related compound libraries

Choose Selective JAK Inhibitors

Biological Activity

Description XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.
Features Orally bioavailable JAK2-selective inhibitor and has been tested in Phase I clinical trials for treatment of Myelofibrosis.
Targets
JAK2 [1]
(Cell-free assay)		 PDGFRβ [1]
(Cell-free assay)		 JAK1 [1]
(Cell-free assay)		 FLT3 [1]
(Cell-free assay)		 JAK3 [1]
(Cell-free assay)
2.2 nM 125.4 nM 134.3 nM 139.7 nM 214.2 nM
In vitro
In vitro XL019 is a highly selective JAK2 inhibitor, binds to the active site of JAK2 displaying >50-fold selectivity against JAK1 and TYK2. XL019 reveals a desirable CYP (1A2, 2C9, 2D6, 3A4 ≥20 μM), hERG (16 μM), and P-glycoprotein inhibition (>20 μM) profile. [1] XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. XL019 showed more than 10-fold selective inhibition (IC50 = 64 nM) of STAT5 phosphorylation following EPO stimulation of erythroid cells compared with other cell systems. [2]
In Vivo
In vivo XL019 significantly inhibits downstream markers pSTAT1 and pSTAT3 after administration 30, 100, and 300 mg/kg resulting in an ED50 of 42 mg/kg (pSTAT1) and 210 mg/kg (pSTAT3). XL019 has a superior pharmacodynamic profile and exhibits good oral absorption, and modest clearance and half life across species. XL019 inhibits of HEL.92.1.7 xenograft tumors growth in mice. It demonstrates 60% and 70% inhibition when dosed orally at 200 mg/kg and 300 mg/kg respectively twice a day for 14 days. Dosing at 300 mg/kg bid provided an 11.3-fold increase in apoptosis relative to vehicle control. [1]
Animal Research Animal Models HEL.92.1.7 xenograft
Dosages 100 mg/kg, 200 mg/kg, 300 mg/kg, bid
Administration P.O.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00595829 Terminated Polycythemia Vera Exelixis December 2007 Phase 1
NCT00522574 Terminated Myeloproliferative Disorders|Myelofibrosis|Polycythemia Vera|Thrombocythemia Essential Exelixis August 2007 Phase 1

Chemical lnformation & Solubility

Molecular Weight 444.53 Formula

C25H28N6O2
CAS No. 945755-56-6 SDF Download XL019 SDF
Smiles C1CC(NC1)C(=O)NC2=CC=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 16 mg/mL ( (35.99 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy XL019 | XL019 supplier | purchase XL019 | XL019 cost | XL019 manufacturer | order XL019 | XL019 distributor